# IMpassion050 (NCT03726879)

> A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03726879
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Breast Cancer
- Interventions: Atezolizumab; Placebo; Doxorubicin; Cyclophosphamide; Paclitaxel; Trastuzumab; Pertuzumab; Trastuzumab Emtansine
- Enrollment: 454
- Primary outcome: Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)
- Primary outcome: pCR in the ITT Population

## Commentary we found

- Podcasts: 4
- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=impassion050-nct03726879

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03726879", "email": "<work email>"}; the inbox owner confirms by the emailed link.